NASDAQ:IOBT - Nasdaq - US4497781090 - Common Stock - Currency: USD
1.5
+0.02 (+1.35%)
The current stock price of IOBT is 1.5 USD. In the past month the price increased by 50%. In the past year, price increased by 14.5%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.65 | 338.27B | ||
AMGN | AMGEN INC | 14.06 | 156.91B | ||
GILD | GILEAD SCIENCES INC | 14.12 | 135.96B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 116.19B | ||
REGN | REGENERON PHARMACEUTICALS | 11.7 | 55.99B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 38.93B | ||
ARGX | ARGENX SE - ADR | 99.99 | 35.11B | ||
ONC | BEONE MEDICINES LTD-ADR | 6.72 | 28.39B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.35B | ||
NTRA | NATERA INC | N/A | 22.77B | ||
BIIB | BIOGEN INC | 8.41 | 19.50B | ||
INSM | INSMED INC | N/A | 17.85B |
IO Biotech, Inc. engages in the development of immune modulating cancer therapies based on its T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The firm develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The firm is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.
IO BIOTECH INC
Ole Maaloes Veh 3
COPENHAGEN DK
Employees: 74
Phone: 4570702980
The current stock price of IOBT is 1.5 USD. The price increased by 1.35% in the last trading session.
The exchange symbol of IO BIOTECH INC is IOBT and it is listed on the Nasdaq exchange.
IOBT stock is listed on the Nasdaq exchange.
12 analysts have analysed IOBT and the average price target is 9.69 USD. This implies a price increase of 546% is expected in the next year compared to the current price of 1.5. Check the IO BIOTECH INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
IO BIOTECH INC (IOBT) has a market capitalization of 98.82M USD. This makes IOBT a Micro Cap stock.
IO BIOTECH INC (IOBT) currently has 74 employees.
IO BIOTECH INC (IOBT) has a support level at 1.49 and a resistance level at 1.61. Check the full technical report for a detailed analysis of IOBT support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
IOBT does not pay a dividend.
IO BIOTECH INC (IOBT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.49).
The outstanding short interest for IO BIOTECH INC (IOBT) is 0.26% of its float. Check the ownership tab for more information on the IOBT short interest.
ChartMill assigns a technical rating of 9 / 10 to IOBT. When comparing the yearly performance of all stocks, IOBT is one of the better performing stocks in the market, outperforming 92.93% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to IOBT. IOBT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months IOBT reported a non-GAAP Earnings per Share(EPS) of -1.49. The EPS increased by 20.32% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -215.27% | ||
ROE | -372.63% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 78% to IOBT. The Buy consensus is the average rating of analysts ratings from 12 analysts.